VRTX

Stocks To Watch: Halozyme Therapeutics Sees RS Rating Rise To 92

Tablet displaying intraday stock performance

On Thursday, Halozyme Therapeutics ( HALO ) cleared an important performance benchmark, seeing its Relative Strength ( RS ) Rating jump into the 90-plus percentile with an improvement to 92, up from 89 the day before.

[ibd-display-video id=2102289 width=50 float=left autostart=true] This exclusive rating from Investor's Business Daily tracks price performance with a 1 (worst) to 99 (best) score. The grade shows how a stock's price behavior over the last 52 weeks stacks up against all the other stocks in our database.

Over 100 years of market history shows that the stocks that go on to make the biggest gains often have an RS Rating of over 80 in the early stages of their moves.

See How IBD Helps You Make More Money In Stocks

Halozyme Therapeutics has climbed more than 5% past a 15.15 entry in a first-stage cup without handle , meaning it's now out of a proper buy zone. Look for the stock to create a new chance to pick up shares like a three-weeks tight or pullback to the 50-day or 10-week moving average.

Regarding top and bottom line numbers, the company has posted rising EPS growth in each of the last three reports. Sales growth has also risen over the same time frame.

The company holds the No. 67 rank among its peers in the Medical-Biomed/Biotech industry group. Corcept Therapeutics ( CORT ), Ligand Pharmaceuticals ( LGND ) and Vertex Pharmaceuticals ( VRTX ) are among the top 5 highly rated stocks within the group.

RELATED:

Biotech And Pharmaceutical Industry And Stock News

Which Stocks Are Showing Rising Relative Strength?

Why Should You Use IBD's Relative Strength Rating?

How Relative Strength Line Can Help You Judge A Stock

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

More Related Articles

Info icon

This data feed is not available at this time.

Sign up for Smart Investing to get the latest news, strategies and tips to help you invest smarter.